Amprion announces SYNTap™ Biomarker Test for early detection of Parkinson's Disease (PD), Lewy Body Dementia (LBD), and Alzheimer's Disease (AD)

San Francisco, CA (PRWEB) October 06, 2021 -- Amprion has announced the commercial rollout of its innovative SYNTap Biomarker Test, a first-in-class

Related Keywords

Rhode Island ,United States ,New York ,California ,National Institutes Of Health ,Maryland ,San Diego ,Pennsylvania ,Russell Lebovitz ,Claudio Soto ,Luis Concha ,University Of Texas Mcgovern Medical School ,Amprion Physicians Center ,Alzheimer Drug Discovery Foundation ,Michaelj Fox Foundation ,Amprion Rd Assoc Director ,Amprion Co Founder ,Chief Scientific ,Biomarker Test ,Lewy Body Dementia ,Multiple System Atrophy ,Seed Aggregation Assay ,Chief Scientific Officer Claudio Soto ,Device Designation ,National Institutes ,Drug Discovery Foundation ,Texas Mcgovern Medical School ,Press Release ,